LSV Asset Management cut its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI – Free Report) by 27.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 404,802 shares of the biopharmaceutical company’s stock after selling 155,119 shares during the quarter. LSV Asset Management’s holdings in Puma Biotechnology were worth $2,409,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH raised its position in Puma Biotechnology by 405.0% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 198,508 shares of the biopharmaceutical company’s stock worth $1,054,000 after buying an additional 159,200 shares during the last quarter. Ritholtz Wealth Management raised its position in Puma Biotechnology by 47.4% during the 4th quarter. Ritholtz Wealth Management now owns 694,001 shares of the biopharmaceutical company’s stock worth $4,129,000 after buying an additional 223,234 shares during the last quarter. Baron Wealth Management LLC raised its position in Puma Biotechnology by 62.6% during the 4th quarter. Baron Wealth Management LLC now owns 35,392 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 13,625 shares during the last quarter. D Orazio & Associates Inc. raised its position in Puma Biotechnology by 112.5% during the 3rd quarter. D Orazio & Associates Inc. now owns 31,933 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 16,906 shares during the last quarter. Finally, State of Wyoming purchased a new position in Puma Biotechnology during the 3rd quarter worth approximately $68,000. 61.29% of the stock is owned by hedge funds and other institutional investors.
Puma Biotechnology Price Performance
NASDAQ:PBYI opened at $7.27 on Wednesday. The firm has a market cap of $370.04 million, a price-to-earnings ratio of 15.15 and a beta of 1.24. The company has a 50 day moving average price of $7.00 and a 200-day moving average price of $6.36. Puma Biotechnology, Inc. has a 1-year low of $3.03 and a 1-year high of $7.90.
Wall Street Analysts Forecast Growth
PBYI has been the subject of a number of recent research reports. Weiss Ratings lowered shares of Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Wall Street Zen lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold”.
Check Out Our Latest Stock Report on PBYI
About Puma Biotechnology
Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.
The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.
Featured Stories
- Five stocks we like better than Puma Biotechnology
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology, Inc. (NASDAQ:PBYI – Free Report).
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
